Ratings Harm Reduction Group AB

Equities

End-of-day quote NORDIC GROWTH MARKET Other stock markets 03:30:00 07/06/2024 am IST			5-day change	1st Jan Change
0.21 ^SEK	+5.26%		+5.26%	+43.84%

30/05	Harm Reduction Group AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
28/02	Harm Reduction Group AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
The stock, which is currently worth 2023 to 0.63 times its sales, is clearly overvalued in comparison with peers.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
HARM REDUCTION GROUP AB	+43.84%	5.86M		-
CHINA TOBACCO INTERNATIONAL (HK) COMPANY LIMITED	+73.05%	1.51B		-
PLANET 13 HOLDINGS INC.	-11.63%	180M	-	-
AMCON DISTRIBUTING COMPANY	-29.58%	86.56M	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality